40% Pop: Is this Ground Breaking Biotech Still a Buy?

With ground breaking cystic fibrosis treatment data, Vertex (Nasdaq: VRTX) shares surged 40% in a single day last week. Kalydeco is already approved to treat are rare mutation occurring in 5% of cystic fibrosis suffers, but by combining it with experimental drug VX-809, Vertex is potentially bringing its treatment to nearly half of the CF population. Vertex's drugs special is that they treat the underlying cause of the disease and not just attempt to mitigate symptoms.

In this episode of Where The Money Is, Motley Fool health care analysts David Williamson and Michael Douglass give investors the background of Vertex, explain the sales potential of the CF treatment, discuss some concerns with the data, and whether it is to late to jump on the stock's bandwagon. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

 


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 3012140, ~/Articles/ArticleHandler.aspx, 7/28/2014 4:53:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 16,982.59 22.02 0.13%
S&P 500 1,978.91 0.57 0.03%
NASD 4,444.91 -4.66 -0.10%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/28/2014 4:00 PM
VRTX $95.56 Down -0.19 -0.20%
Vertex Pharmaceuti… CAPS Rating: ***
GILD $91.46 Up +1.62 +1.80%
Gilead Sciences CAPS Rating: ****

Advertisement